ANTH Anthera Pharmaceuticals, Inc.

-0.07  -4%
Previous Close 1.74
Open 1.75
Price To book 7.34
Market Cap 16.83M
Shares 10,076,000
Volume 125,462
Short Ratio 2.27
Av. Daily Volume 2,041,180

SEC filingsSee all SEC filings

  1. 8-K - Current report 17870394
  2. 8-K - Current report 17855460
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830773
  4. 8-K - Current report 17830371
  5. 8-K - Current report 17795515

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due end of 2017 or early 2018.
Sollpura - RESULT
Exocrine pancreatic insufficiency
Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017.
IgA nephropathy
Top-line data released December 27, 2016 - missed primary endpoint.
Sollpura (liprotamase)
Cystic fibrosis who suffer from exocrine pancreatic insufficiency
Phase 3 trial did not meet endpoints - November 10, 2016.

Latest News

  1. Anthera Announces First Patient Screened in RESULT Pivotal Phase 3 Clinical Study of Sollpura
  2. Anthera reports 1Q loss
  3. Anthera Pharmaceuticals Provides Business Update and Reports 2017 First Quarter Financial Results
  4. Anthera Pharmaceuticals Announces 1-for-8 Reverse Split of Stock
  5. Axovant Sciences (AXON) Shows Strength: Stock Jumps 9.2%
  6. ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study
  7. ANTH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Anthera Pharmaceuticals, Inc. and a Lead Plaintiff Deadline of April 17, 2017
  8. Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nephropathy
  9. DEADLINE ALERT: Brower Piven Reminds Investors Of The Upcoming Deadline In Class Action Lawsuit And Encourages Investors With Losses In Excess of $100,000 From Investment In Anthera Pharmaceuticals, Inc. To Contact The Firm
  10. ETFs with exposure to Anthera Pharmaceuticals, Inc. : April 7, 2017
  11. INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors It Has Filed a Complaint to Recover Losses Suffered by Investors in Anthera Pharmaceuticals, Inc. -- Lead Plaintiff Deadline of April 17, 2017 -- ANTH
  12. Bill Ackman Apologizes for Valeant Investment Error
  13. Anthera's Sollpura On Par With Pancreaze Study
  14. Anthera Announces Positive Results from the Extension Period of the SOLUTION Study of Sollpura
  15. Cara Therapeutics (CARA) Shows Strength: Stock Up 5.2%
  16. Will Endo's Troubles Continue to Dent Performance in 2017?
  17. ETFs with exposure to Anthera Pharmaceuticals, Inc. : March 27, 2017
  18. Shire (SHPG) Rare Disease Drug Gets Fast Track Designation
  19. Anthera Pharmaceuticals, Inc. :ANTH-US: Earnings Analysis: 2016 By the Numbers : March 21, 2017